Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418745 | 0.89 | ROCK2 (0.68) | ROCK2ROCK1NPC1JAK2RAB9A | |
| SCHEMBL5409240 | 0.88 | ROCK2 (0.67) | ROCK2ROCK1NPC1JAK2RAB9A | |
| SCHEMBL5413153 | 0.78 | ROCK2 (0.71) | ROCK2ROCK1NPC1JAK2RAB9A | |
| SCHEMBL15147814 | 0.78 | ROCK2 (1.00) | ROCK2ROCK1NPC1JAK2RAB9A | |
| SCHEMBL17776529 | 0.77 | ROCK2 (0.71) | ROCK2ROCK1NPC1JAK2RAB9A | |
| SCHEMBL5414857 | 0.76 | ROCK2 (0.71) | ROCK2ROCK1NPC1JAK2RAB9A | |
| SCHEMBL5414796 | 0.76 | ROCK2 (0.87) | ROCK2ROCK1NPC1JAK2RAB9A | |
| SCHEMBL5407770 | 0.76 | ROCK2 (0.66) | ROCK2ROCK1NPC1JAK2RAB9A | |
| SCHEMBL9348553 | 0.76 | NPC1 (0.72) | ROCK2ROCK1NPC1JAK2RAB9A | |
| SCHEMBL2571077 | 0.76 | ROCK2 (0.74) | ROCK2ROCK1NPC1JAK2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ROCK2 2/4885ROCK1 1/4885NPC1 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.